EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations

Blood

Volumn 125, Issue 1, 2015, Pages 140-143

  Lavallée, Vincent Philippe ^a,b   Gendron, Patrick ^a   Lemieux, Sébastien ^a,c   D'Angelo, Giovanni ^b   Hébert, Josée ^a,b,d   Sauvageau, Guy ^a,b,d  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RAS PROTEIN; TRANSCRIPTOME; VASOACTIVE INTESTINAL POLYPEPTIDE; APOPTOSIS REGULATORY PROTEIN; DNA BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; MECOM PROTEIN, HUMAN; MYCT1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PREX2 PROTEIN, HUMAN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 7; ECOTOPIC VIRAL INTEGRATION SITE 1 GENE; GENE; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IKZF1 GENE; MECOM GENE; MONOSOMY 7; MYCT1 GENE; PAWR GENE; PREX2 GENE; RNA SEQUENCE; RNA SPLICING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PROTO ONCOGENE;

APOPTOSIS REGULATORY PROTEINS; CHROMOSOMES, HUMAN, PAIR 7; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84920554128     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-591529     Document Type: Article

References (23)

1. Steinleitner K, Rampetsreiter P, Köffel R, et al. EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 2012; 32(11): 4883-4889.
2. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003; 101(3): 837-845.
3. Gröschel S, Schlenk RF, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2013; 31(1): 95-103.
4. Grimwade D, Hills RK, Moorman AV, et al.; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354-365.
5. Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014; 99(5): 821-829.
6. Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010; 28(24): 3890-3898.
7. Weisser M, Haferlach C, Haferlach T, Schnittger S. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. Leuk Lymphoma. 2007; 48(11): 2145-2151.
8. Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia. 2011; 25(5): 874-877.
9. Sun J, Konoplev SN, Wang X, et al. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol. 2011; 24(3): 384-389.
10. Papaemmanuil E, Cazzola M, Boultwood J, et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15): 1384-1395.
11. Jeromin S, Haferlach T, Grossmann V, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2013; 98(2):e15-e17.
12. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191): 110-114.
13. Jäger R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010; 24(7): 1290-1298.
14. Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev. 2000; 14(17): 2146-2160.
15. Mullighan CG, Su X, Zhang J, et al.; Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5): 470-480.
16. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014; 157(2): 369-381.
17. Pandiella A, Montero J. Molecular pathways: P-Rex in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(17): 4564-4569.
18. Fine B, Hodakoski C, Koujak S, et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 2009; 325(5945): 1261-1265.
19. Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res. 2006; 66(6): 2889-2892.
20. Yin X, Grove L, Rogulski K, Prochownik EV. Myc target in myeloid cells-1, a novel c-Myc target, recapitulates multiple c-Myc phenotypes. J Biol Chem. 2002; 277(22): 19998-20010.
21. Kustikova OS, Schwarzer A, Stahlhut M, et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 2013; 27(5): 1127-1138.
22. Kawakami M, Kimura T, Kishimoto Y, et al. Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38-cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells. Leukemia. 2004; 18(5): 912-921.
23. Nam C, Case AJ, Hostager BS, O'Dorisio MS. The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation. J Mol Neurosci. 2009; (37): (2): 160-167.